Sun Pharma introduces STARIZO in India for skin infections
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Majority of organizations are looking to increase investments in public and hybrid cloud
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Subscribe To Our Newsletter & Stay Updated